MOESM1 of Effects of linagliptin on endothelial function and postprandial lipids in coronary artery disease patients with early diabetes: a randomized, placebo-controlled, double-blind trial Norbert Tripolt Felix Aberer Regina Riedl Jasmin Url Gudrun Dimsity Andreas Meinitzer Tatjana Stojakovic Faisal Aziz Ronald Hรถdl Gabriele Brachtl Dirk Strunk Marianne Brodmann Franz Hafner Harald Sourij 10.6084/m9.figshare.6286979.v1 https://springernature.figshare.com/articles/journal_contribution/MOESM1_of_Effects_of_linagliptin_on_endothelial_function_and_postprandial_lipids_in_coronary_artery_disease_patients_with_early_diabetes_a_randomized_placebo-controlled_double-blind_trial/6286979 Additional file 1: Table S1. Change in cell counts from baseline in linagliptin vs. Placebo groups. FMD: flow mediated dilatation; MTT: meal tolerance test; sVCAM-1: soluble vascular cell adhesion molecule-1; sICAM-1: soluble intercellular adhesion molecule-1. 2018-05-17 05:00:00 Linagliptin Flow mediated dilatation RCT DPP-4 inhibitor Type 2 diabetes Coronary artery disease Endothelial function